قالب وردپرس درنا توس
Home / Business / Sacramento has been selected as the testing site for COVID-19 vaccine

Sacramento has been selected as the testing site for COVID-19 vaccine



Sacramento has been selected as a testing site for COVID-19 vaccine. Both UC Davis Medical Center and Kaiser Permanente are participating in vaccine testing through a partnership with Pfizer. The trial will expand 120 locations with a goal of including 30,000 applicants worldwide. “What we want the community to know is that this research is really important. It is the first step in developing a vaccine for COVID, ”said UC Davis Principal Allison Brashear. UC Davis Medical Center explains that they are focusing on enrollment of Latino and Black participants – communities disproportionately affected by COVID-19. “Anyone between 1

8 and 55 is in the first group, and soon after will be those over 55. And, we want people with reasonable health,” Brashear explained. Kaiser Permanente is looking for candidates who are 18 to 85 years old and are generally healthy but are considered to be at high risk from employment, living circumstances, or part of the community considered at risk for COVID-19. . “We don’t inject any viral proteins ourselves. “We do not inject any type of virus into individuals,” says Nicola Klein, of the Kaiser Permanente Vaccine Research Center. “But MRNA – what’s called the MRNA of nucleic acid technology – and includes DNA vaccines, that you’ve probably heard of. This is a new technology for vaccines. There are currently no licensed vaccines that have been developed using this technology. But, it is genetic material. It cannot replicate itself or do anything on its own. ”Kaiser Permanente is also part of another COVID-19 vaccine trial, co-developed by the National Institute of Allergy and Infectious Diseases and Moderna. UC Davis explains if the vaccine candidate’s success continues, regulatory review could happen as early as October. If approved, Pfizer and BioNTech plan to deliver up to 100 million. dose by the end of 2020 and about 1.3 billion doses by the end of 2021.

Sacramento has been selected as a testing site for COVID-19 vaccine. Both UC Davis Medical Center and Kaiser Permanente are participating in vaccine testing through a partnership with Pfizer.

The trial will span 120 locations with a goal of including 30,000 applicants worldwide.

“What we want the community to know is that this research is really important. It is the first step in developing a vaccine for COVID, ”said UC Davis Principal Allison Brashear.

UC Davis Medical Center explains that they are focusing on enrollment of Latino and Black participants – communities disproportionately affected by COVID-19.

“Anyone between 18 and 55 is in the first group, and soon after will be those over 55. And, we want people with reasonable health,” Brashear explained.

Kaiser Permanente is looking for candidates who are 18 to 85 years old and are generally healthy but are considered to be at high risk from employment, living circumstances, or part of the community considered at risk for COVID-19. .

“We don’t inject any viral proteins ourselves. “We do not inject any type of virus into individuals,” says Nicola Klein, of the Kaiser Permanente Vaccine Research Center. “But MRNA – what’s called the MRNA of nucleic acid technology – and includes DNA vaccines, that you’ve probably heard of. This is a new technology for vaccines. There are currently no licensed vaccines that have been developed using this technology. But, it is genetic material. It can’t replicate itself or do anything on its own.

Kaiser Permanente is also part of another COVID-19 vaccine trial, co-developed by the National Institute of Allergy and Infectious Diseases and Moderna.

UC Davis explains if a vaccine candidate’s success continues, regulatory review could occur as early as October.

If approved, Pfizer and BioNTech plan to deliver up to 100 million doses by the end of 2020 and around 1.3 billion doses by the end of 2021.


Source link